Insider · CIK 0001571320

Regan Daniel Paul

Reports to the SEC for 2 companies · NEW YORK, NY

sec.gov

Transactions

Companies

Filings

CIK

0001571320

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2018-12-12	KERYX BIOPHARMACEUTICALS INCD Disposition to Issuer	Director	DDisposition to Issuer	−60K sh	—	—	0
2018-12-12	KERYX BIOPHARMACEUTICALS INCStock OptionD Disposition to Issuer	Director	DDisposition to Issuer	−200K sh	—	—	0
2018-06-30	KERYX BIOPHARMACEUTICALS INCA Award	Director	AAward	+10K sh	—	—	60,000
2018-06-30	KERYX BIOPHARMACEUTICALS INCStock Options (right to buy)A Award	Director	AAward	+30K sh	—	—	30,000
2017-06-09	KERYX BIOPHARMACEUTICALS INCA Award	Director	AAward	+10K sh	—	—	50,000
2017-06-09	KERYX BIOPHARMACEUTICALS INCStock Options (right to buy)A Award	Director	AAward	+30K sh	—	—	30,000
2016-05-26	KERYX BIOPHARMACEUTICALS INCA Award	Director	AAward	+10K sh	—	—	40,000
2016-05-26	KERYX BIOPHARMACEUTICALS INCStock Options (right to buy)A Award	Director	AAward	+30K sh	—	—	30,000
2015-06-17	KERYX BIOPHARMACEUTICALS INCA Award	Director	AAward	+10K sh	—	—	30,000
2015-06-17	KERYX BIOPHARMACEUTICALS INCStock Option (right to buy)A Award	Director	AAward	+30K sh	—	—	30,000
2015-01-30	INTERCEPT PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+9,847 sh	$37.69	+$371K	11,111
2015-01-30	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−6,847 sh	$200.07	−$1.37M	4,264
2015-01-30	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−1,207 sh	$201.50	−$243K	3,057
2015-01-30	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−793 sh	$202.49	−$161K	2,264
2015-01-30	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−800 sh	$205.87	−$165K	1,464
2015-01-30	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−200 sh	$208.08	−$41.6K	1,264
2015-01-30	INTERCEPT PHARMACEUTICALS, INC.Option to Purchase Common StockM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−9,847 sh	—	—	92,028
2015-01-05	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−146 sh	$176.49	−$25.8K	1,264
2014-08-12	INTERCEPT PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+8,124 sh	$37.69	+$306K	9,534
2014-08-12	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−200 sh	$305.38	−$61.1K	9,334
2014-08-12	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−100 sh	$306.91	−$30.7K	9,234
2014-08-12	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−500 sh	$310.10	−$155K	8,734
2014-08-12	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−500 sh	$311.88	−$156K	8,234
2014-08-12	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−200 sh	$312.77	−$62.6K	8,034
2014-08-12	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−800 sh	$313.84	−$251K	7,234
2014-08-12	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−600 sh	$314.93	−$189K	6,634
2014-08-12	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−200 sh	$316.62	−$63.3K	6,434
2014-08-12	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−400 sh	$317.70	−$127K	6,034
2014-08-12	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−400 sh	$319.47	−$128K	5,634
2014-08-12	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−200 sh	$321.44	−$64.3K	5,434
2014-08-12	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−100 sh	$322.92	−$32.3K	5,334
2014-08-12	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−100 sh	$326.03	−$32.6K	5,234
2014-08-12	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−300 sh	$327.89	−$98.4K	4,934
2014-08-12	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−594 sh	$329.59	−$196K	4,340
2014-08-12	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−206 sh	$330.91	−$68.2K	4,134
2014-08-12	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−200 sh	$331.92	−$66.4K	3,934
2014-08-12	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−100 sh	$335.01	−$33.5K	3,834
2014-08-12	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−200 sh	$336.47	−$67.3K	3,634
2014-08-12	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−100 sh	$337.17	−$33.7K	3,534
2014-08-12	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−300 sh	$341.20	−$102K	3,234
2014-08-12	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−300 sh	$342.05	−$103K	2,934
2014-08-12	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−800 sh	$343.80	−$275K	2,134
2014-08-12	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−500 sh	$344.73	−$172K	1,634
2014-08-12	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−224 sh	$346.68	−$77.7K	1,410
2014-08-12	INTERCEPT PHARMACEUTICALS, INC.Option to Purchase Common StockM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−8,124 sh	—	—	101,875
2014-07-03	INTERCEPT PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+1 sh	$37.69	+$37.69	1,411
2014-07-03	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−1 sh	$250.00	−$250	1,410
2014-07-03	INTERCEPT PHARMACEUTICALS, INC.Option to Purchase Common StockM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−1 sh	—	—	109,999
2014-03-05	INTERCEPT PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+20K sh	$37.69	+$754K	20,000
2014-03-05	INTERCEPT PHARMACEUTICALS, INC.S Sale	Chief Commercial Officer	SSale	−500 sh	$426.06	−$213K	19,500

Recent filings

Accepted (ET)
Dec 134
Regan Daniel Paul0000899243-18-030888
SEC(opens sec.gov)
Jul 124
Regan Daniel Paul0001114220-18-000075
SEC(opens sec.gov)
Jun 204
KERYX BIOPHARMACEUTICALS INC0000899243-17-016759
SEC(opens sec.gov)
May 274
KERYX BIOPHARMACEUTICALS INC0000899243-16-021128
SEC(opens sec.gov)
Jun 184
KERYX BIOPHARMACEUTICALS INC0001209191-15-054839
SEC(opens sec.gov)
Feb 34
INTERCEPT PHARMACEUTICALS INC0001144204-15-005703
SEC(opens sec.gov)
Jan 74
INTERCEPT PHARMACEUTICALS INC0001144204-15-001258
SEC(opens sec.gov)
Aug 154
INTERCEPT PHARMACEUTICALS INC0001144204-14-050902
SEC(opens sec.gov)

Companies

Address

C/O INTERCEPT PHARMACEUTICALS, INC. 18 DESBROSSES ST.

NEW YORK, NY, 10013